Background: Immune checkpoint inhibitors (specifically the anti-CTLA-4 antibody ipilimumab, and the anti-PD-1 antibodies nivolumab and pembrolizumab, have revolutionized the treatment of advanced malignancies. However, by virtue of their mechanism of action -that is, loss of T-cell inhibition and impaired self-tolerance, patients with underlying autoimmune and rheumatologic diseases were typically excluded from the clinical trials leading to the approval of these agents. Limited data, typically of single checkpoint inhibitors, exist for their safety in patients with autoimmune diseases. However, the risk for rheumatologic disease flare in patients exposed to checkpoint inhibitors is unknown. Objectives: To determine the risk of rheumatologic disease flare in patients receiving checkpoint inhibitor therapy. Methods: We retrospectively studied all patients who had received a checkpoint inhibitor (i.e. ipilimumab, nivolumab, pembrolizumab, or any combination thereof) for any malignancy on the Mayo Clinic Rochester, Minnesota campus between January 1st, 2011 and May 16th, 2016 (approximately 5,200 patients.) Of these patients, we identified those with preexisting rheumatologic disease according to specific diagnostic codes. Results: Of the 16 patients identified (13 [81%] female; median [range] age, 68.5 [34-86] y), 6 had inflammatory arthritis, 3 had polymyalgia rheumatica, 2 had lupus, 2 had Sjogren's syndrome, 1 had temporal arteritis, 1 had IBD-associated spondyloarthropathy and 1 had gout. 6%] ). Notably, in all cases, checkpoint inhibitor therapy was offered after failure of numerous other chemotherapies. Ten (62.5%) patients were on immunosuppressive therapy (mainly low dose prednisone and methotrexate) at the time of cancer diagnosis, and the majority (10 [62.5%]) were well-controlled/in remission from the standpoint of their rheumatologic disease. Three (19%) patients had flares of their rheumatologic disease after treatment for the following cancers as noted: Patient 1 -temporal arteritisnivolumab -non-small cell lung cancer, Patient 2 -Sjogren's (severe sicca)-pembrolizumab -melanoma, and Patient 3 -spondylitis-ipilimumab/pembrolizumab combination -melanoma. All flares responded to steroids or supportive therapy. Checkpoint inhibitor therapy was discontinued in all three patients for the following reasons: Patient 1 -flare of temporal arteritis, Patients 2 & 3 -cancer progression. Conclusions: To our knowledge, we have identified the largest cohort (16) of patients from a single academic with preexisting rheumatologic disease who had been exposed to checkpoint inhibitor therapy for advanced malignancy. Of these patients, only a minority experienced a flare of their disease during cancer treatment, and responded to standard therapies. Whilst the biological processes underlying this relationship are not understood, vascular dysfunction may play a role (1, 2). However, research is yet to examine the association between sedentary behaviour and vascular function in healthy adults and/or clinical populations. Studies investigating this relationship in RA, will help to determine the extent to which sedentary behaviour may represent a modifiable risk factor for CVD in these patients. Objectives: To investigate the cross-sectional associations between sedentary behaviour and microvascular and large vessel endothelial function among patients with RA. Methods: Fifty-three patients with RA participated in the study (M age=52.9±12.8, 72% female). Laser Doppler imaging with iontophoresis was used to assess microvascular endothelium-dependent (acetylcholine, ACh) and endotheliumindependent (sodium nitroprusside, SNP) function. Large vessel endotheliumdependent and endothelium-independent functions were measured via flowmediated dilation (FMD) and glyceryl trinitrate dilation (GTN), respectively. Sedentary behaviour was self-reported via the International Physical Activity Questionnaire (hours/week sitting). Data were analysed using multiple linear regressions adjusted for traditional CVD risk factors; age, gender, total cholesterol, smoking status, family history of CVD, hypertension and body-mass-index. Results: Sitting time (hours/week, M =39.2±17.9) was significantly negatively related to % increase in perfusion in response to ACh (β=−0.30, p<0.05) and SNP (β=−0.37, p<0.01) after adjustment for traditional CVD risk factors. Sitting time accounted for 8% and 12% of the variance in microvascular endothelium-dependent function (ACh) and endothelium-independent function (SNP), respectively (traditional CVD risk factors, R 2 =0.3). No significant associations were observed between self-reported sitting time and large vessel endothelium-dependent vasodilation (FMD, β=0.16, p=0.29) Background: From Community based COPCORD (community oriented program for control of rheumatic diseases) study in Bangladesh about a quarter of people is suffering from musculoskeletal disorders. But the study was conducted over a small number of samples and some specific localities of the country. So further study was required, covering the whole Bangladesh to justify this high prevalence. Objectives: To determine the prevalence of musculoskeletal symptoms and specific rheumatic disorders in adult population of Bangladesh. Methods: In this survey, a total of 2000 individuals aged 18 years or older were selected in twenty clusters (primary sample unit) from the seven divisions of the country. Modified COPCORD (Community Oriented Program for Control of Rheumatic Disorders) questionnaire was used to detect positive respondents. Standard criteria were used for diagnosing rheumatic disorders. Clinical judgment was used to solve diagnostic problems. Results: In total 1843 individuals were interviewed with a response rate of 92.1%. The point prevalence of musculoskeletal pain was 33.7%. It was higher in women (38.7%) than men (28.4%) and higher in rural (34.5%) than that in urban (32.4%) areas. Higher prevalence rates were observed in homemakers (16.0%), laborers (3.0%), business professionals (2.9%) and cultivators (2.8%). Low back (23.3%), knee (12.7%) and shoulder (6.1%) were the most frequent site of complaint. Non specific low back pain (12.7%) and knee osteoarthritis (7.3%) were the two top ranking disorders. The prevalence of rheumatoid arthritis was 1.6% and spondyloarthritis 1.2%. 5.5% of the respondents had disability from rheumatic problems. Conclusions: About one third of the Bangladeshi adults suffer from musculoskeletal pain at a given point of time. There are residence and gender variation in the prevalence rates. Low back and knee pain were the principal sites of complaints. Background: The increased risk of opportunistic infections (OIs) in rheumatoid arthritis (RA) patients who started biologic disease modifying anti-rheumatic drugs (DMARDs) has been well known. However, it has not been studied regarding the increased risk of OIs in the early stage of RA. Objectives: To study the increased risk of incidence rate (IR) of OIs in early RA patients compared with established RA patients, and to evaluate the risk factors for developing the OIs in the early stage of RA. Methods: Retrospective cohorts of early and established RA patients were conducted independently using the Korean National Healthcare claims database. Early RA patients (n=14,081) were identified in 2010 having disease free period for 1 year before index date, and receiving continuous treatment for over three years. Established RA patients (n=226, 838) were recruited between 2010 and 2012 with using the ICD10 code of RA and any DMARD use. Follow-up started on the index date and ended on the data of the development of OIs, at 12 months, or at the time of death. The incidence rates of OIs were compared between two groups by calculating incidence rates ratio (IRR) and standardized incidence ratio (SIR) for overall or each OIs. The multivariable regression model was used to evaluate the risk factors for OIs in the early stage of RA. RA = rheumatoid arthritis, SIR = standardized incidence ratio, PY = person year, N = number, IR = incidence rate, CI = confidence interval.
Results:
The IRs of overall OI in early and established RA patients were 3.81 (95% CI 3.52-4.11)/100PY and 3.67 (95% CI, 3.59-3.74)/100PY, respectively. The SIR for overall OIs in early RA patients was 1.14 (95% CI, 1.05-1.23).
The herpes zoster (SIR 1.12, 95% CI 1.03- Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that runs an unpredictable disease course. Objectives: We aimed to understand the characteristics and outcomes of incident hospitalisation for conditions other than the underlying disease in SLE patients. Methods: Using whole-population data linkage of hospital admissions and death records in Western Australia (WA) WA between 1980 and 2015, we performed a retrospective analysis for patients where SLE (ICD-9-CM 695.4, 710.0 and ICD-10-AM L93.0 & M32) was a co-existing discharge diagnosis. All SLE patients were age-and gender-matched with hospital controls free of rheumatic disease. We investigated the rate and characteristics of the index hospitalisation for comorbidity and the risk of subsequent death by Kaplan-Meier survival and Cox regression.
